Nasodine (povidone-iodine 0.5%) / Firebrick Pharma - LARVOL DELTA

Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone-iodine nasal spray (Nasodine). (PubMed, Int Forum Allergy Rhinol) - "The extent of iodine absorption from available PVP-I nasal products is unknown. Iodine absorption from use of Nasodine (0.5% PVP-I nasal spray) is not clinically significant."

Journal • P1 data

Confirmatory Phase III study of Nasodine Nasal Spray (povidone-iodine 0.5%) as a symptomatic treatment for early stage common cold in the natural setting. (ANZCTR) - P3 | N=500 | Completed | Sponsor: Firebrick Pharma Limited | Recruiting ➔ Completed

Trial completion • Respiratory Diseases

Phase II Trial of the Impact 0.5% Povidone-Iodine Nasal Spray (Nasodine®) on Shedding of SARS-CoV-2. (PubMed, Laryngoscope) - "A total of 20 doses of Nasodine® nasal spray administered over 2.5 days significantly reduced the titers of viable SARS-CoV-2 virus in the nasal passages of COVID-19 subjects. This is the first study demonstrating the efficacy of a tolerable intranasal formulation of povidone-iodine on viral shedding in COVID-19 subjects. Nasal disinfection may diminish viral transmission to others."

Clinical • Journal • P2 data • Infectious Disease • Novel Coronavirus Disease • Otorhinolaryngology • Respiratory Diseases

In vitro Nasodine Can be an Effective Antibiofilm Agent for Biofilms that May Cause CRS. (PubMed, Laryngoscope) - "Nasodine is highly active against biofilms of S. aureus ATCC 6538 in vitro. Biofilm killing is impeded by the presence of the intact biofilm structure."

Journal • Preclinical • Allergy • Immunology • Inflammation • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Povidone-Iodine Oral Rinse Study (clinicaltrials.gov) - P2 | N=40 | Completed | Sponsor: University of Pennsylvania | Recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Jul 2022

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Also nasodine" (@qewperp)

Combined Nasal, Oropharyngeal Povidone Iodine Plus Glycyrrhizic Acid Sprays, Accelerate Clinical and Laboratory Recovery and Reduces Household Transmission of SARS-CoV-2: A Randomized Placebo-Controlled Clinical Trial. (PubMed, Front Med (Lausanne)) - "In this randomized placebo-controlled clinical study, we tested the effects of intranasal and oropharyngeal delivery of a compound of povidone-iodine 0.5% and glycyrrhizic acid 2.5 mg/ml on the laboratory (PCR) and clinical recovery from SARS-CoV-2 patients and their household contacts...Combined PVI-GA nasal and oropharyngeal spray accelerates both laboratory and clinical recovery of SARS-CoV-2 infected patients in the early phases of the disease and reduces the household spread of the virus; thus, it may play an important role in controlling coronavirus outbreaks. https://pactr.samrc.ac.za, PACTR202101875903773."

Clinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The Efficacy of Oral Antiseptics Against SARS-CoV-2 (clinicaltrials.gov) - P4 | N=75 | Completed | Sponsor: Ataturk University

New P4 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

VEP-COV: Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo (clinicaltrials.gov) - P2; N=200; Completed; Sponsor: DR. MALA KHAN; Recruiting ➔ Completed

Preclinical • Trial completion • Infectious Disease • Novel Coronavirus Disease

PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19) (clinicaltrials.gov) - P1/2; N=45; Recruiting; Sponsor: Stanford University; Trial completion date: Oct 2020 ➔ Jan 2021; Trial primary completion date: Sep 2020 ➔ Dec 2020

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

VEP-COV: Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo (clinicaltrials.gov) - P2; N=200; Recruiting; Sponsor: Pi Research Consultancy Center, Bangladesh

New P2 trial • Infectious Disease • Novel Coronavirus Disease

PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19) (clinicaltrials.gov) - P1/2; N=45; Recruiting; Sponsor: Stanford University; Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • PCR